According to a new report published by We Market Research, titled, Anti-Neprilysin Drug Market size was valued at $ 1,263 Million in 2023, and is estimated to reach $ 2,183 Million by 2033, growing at a CAGR of 4.9% from 2023 to 2033.
Anti-Neprilysin drug are mostly used in the treatment of acute heart failure. Hart failure is chronic progressive condition of heart muscles is unable to pump enough amount of blood to the body parts. The most widely used Anti-Neprilysin drug medication is Sacubitril/valsartan, available under the brand name Entrest. It is composed of the neprilysin inhibiting agent sacubitril and the angiotensin receptor blocking drug valsartan.
The increasing the prevalence of diseases like Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others drive the market growth in the forecasted period. Additionally, rising the incidences of heart diseases, increasing the government support for awareness campaign, robust research and development investment will fuel to drive the Anti-Neprilysin drug market.
Request Free Sample Copy of this Report @ https://wemarketresearch.com/reports/request-free-sample-pdf/anti-neprilysin-drug-market/1326
For instance, as on June 2, 2022, Cipla Inc., an India-based biopharmaceutical and medical company, announced the commercial operation of additional capacity of captive renewable energy power plants in Maharashtra and Karnataka, India. This initiative is designed to fulfill the company’s green energy demands for their manufacturing facilities located in Kurkumbh and Patalganga, both situated in India, as well as their research and development center in Maharashtra. It will effectively replace approximately 70% of the total energy consumption for these units with eco-friendly, renewable energy sources.
Market Dynamics
The growth of the Anti-Neprilysin drug market is significantly driven by increasing prevalence of acute heart failure, an upsurge in government support and surveillance at both national and global levels. Furthermore, substantial investments by major industry players worldwide and increased government funding have played a pivotal role propelling the growth of the market.
For instance, as on the data published in September 2020, by PubMed, a free search engine for biological databases and medical reports, Heart failure impacts over 64 million individuals annually on a global scale. Addressing this condition’s social and economic challenges has emerged as a significant public health priority worldwide.
Furthermore, increasing the product approval given by the regulatory bodies propelling the growth of Anti-Neprilysin drug market. For instance, in February 2015, Novartis International AG a drug manufacturing company announced that the U.S. Food and Drug Administration (FDA) granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). This decision is taken to accelerate the review of therapy or medication which offers a more safety and effectiveness in the treatments, diagnosis and preventions of serious conditions.
However, cost of therapy and the substantial expenses associated with research and development and the extended timeframe needed to bring a new drug in market could potentially impede the growth of the Anti-Neprilysin drug market.
Overall, with the help of existing and modern treatment therapy the Market is expected to witness significant growth in the coming years, driven by the introduction of new therapies and an increasing demand for effective treatments.
Secure a copy of the premium research report@ https://wemarketresearch.com/purchase/anti-neprilysin-drug-market/1326?license=single
Segments
By Drug Type
- Sacubitril
- TD-0714
- STR-324
- PL-265
- LHW-090
- Others
By Indication
- Acute Heart Failure
- Cancer Pain
- Hypertension
- Alzheimer’s Disease
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Top Key Players
The Anti-Neprilysin drug Market is dominated by a few large companies, such as Novartis AG, BIOPROJET, Pharmaleads SA, Cipla Inc, Oceanic Pharmachem Pvt. Ltd., Theravance Biopharm.
Related Reports
Hydrogel-Based Drug Delivery System Market
Digital Twin in Healthcare Market
About We Market Research:
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep-rooted market studies and insightful analysis of different markets.
Media Contact
Company Name: We Market Research
Contact Person: Mr. Robin
Email: Send Email
Country: United States
Website: https://wemarketresearch.com/reports/anti-neprilysin-drug-market/1326